Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

This study tests osilodrostat (brand name Isturisa) — a drug approved for Cushing's syndrome — in people with mild autonomous cortisol secretion (MACS), a condition where one or both adrenal glands produce slightly too much cortisol without causing full-blown Cushing's syndrome. Excess cortisol, even in mild amounts, can increase the risk of osteoporosis, diabetes, and heart disease. **You may be eligible if...** - You are 18 or older - You have mild autonomous cortisol secretion confirmed by a dexamethasone suppression test (cortisol remains above 1.8 µg/dL after the test) - You have a benign adrenal growth (adenoma) confirmed on CT or MRI - You are able to provide informed consent and complete the required study visits **You may NOT be eligible if...** - You have full Cushing's syndrome - You have significant liver disease or other conditions that make the drug unsafe - You are pregnant or may become pregnant - You are already on medications that significantly interact with osilodrostat Talk to your doctor to see if this trial is right for you.